High materiality7/10
UroGen Pharma price target raised to $58 from $42 at Guggenheim
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Analyst target update: URGN target $58 (from $42); posted price $46.43; Firm Guggenheim.
- Target $58; Posted price $46.43; Firm: Guggenheim.
Key facts
- 01
Target: $58
- 02
Posted price: $46.43
- 03
Analyst firm: Guggenheim
- 04
Analyst: Michael Schmidt
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.